美国安进地舒单抗怎么购买？

It is seen as one of the most important growth drivers for Amgen, the world's largest biotechnology company. Desosumab is approved to prevent fractures caused by cancer that has spread to the bones, not to prevent or delay the spread of the cancer. So, how to buy Amgen denosumab in the United States?

Desosumab has not yet been included in the medical insurance in China. Overseas, a box of denosumab produced by Amgen in the United States is only about $1,500. Compared with the same period last year, the price of the original research drug sold in China has dropped. Patients in need can purchase medicines abroad or obtain medicines through domestic professional overseas medical service organizations (such as Medical Companion Travel), which can be delivered directly to their homes to ensure authenticity.

Amgen is principally engaged in the discovery, development, production and sales of innovative drugs for human use, and is committed to exploring the potential of biotechnology for the treatment of patients with serious diseases. As a leader in the global biopharmaceutical industry, Guizhou has strong R&D capabilities and product advantages. It insists on developing in the field of biotechnology for disease treatment. Its main fields include human genome, cancer, neuroscience and small molecule chemistry.

On May 27, 2019, denosumab was approved by the National Medical Products Administration for the treatment of giant cell tumor of bone that is unresectable or whose surgical resection may cause severe functional disability, including adults and adolescent patients with skeletal maturity (defined as at least 1 mature long bone and body weight >45 kg).

Desosumab is easy to use and can be injected subcutaneously by the patient at 60 mg/time with an interval of 6 months. While being treated with denosumab, patients need to take 1000mg of calcium and at least 4001U of vitamin D per day. It is worth noting that unlike bisphosphonates, which have longer-term effects, denosumab does not bind to its receptors for long-term retention.

FDA-approved for use in postmenopausal women with osteoporosis who are at high risk for fracture, to help reduce the incidence of vertebral, non-vertebral and hip fractures in postmenopausal women with osteoporosis. Desosumab is also used to reduce the risk of fractures in patients for whom other current treatments are ineffective or intolerable.